Precision for Medicine Acquires ACT Oncology         


Executive Director, Business Operations

Rob has worked in the clinical research/pharmaceutical services industry for 20 years and joined ACT Oncology in 2000 (formerly Advanced Clinical Trial Solutions, Inc.).   In his current role as Executive Director, Business Operations, Rob directs many of ACT Oncology’s key business functions, including strategic resourcing across ACT’s oncology portfolio, information technology, human resources, and business and operations infrastructure build and management.  Rob is also the Executive Sponsor for select ACT clients with multi-study portfolios, providing support and mentoring to various operations staff.  In addition to the above, Rob also serves on the company’s Executive Team, contributing to the planning and execution of corporate strategy.

Prior to joining ACT Oncology from 1995 to 2000, Rob worked at Covance in Clinical Operations supporting the monitoring and management of oncology studies.  Additionally, Rob had the privilege to work as member of the development team for Herceptin®.  His experience on those trials included the entire spectrum of operations, from the identification of key opinion leaders and investigative sites, through final approval and product registration.  Rob also coordinated the process design and implementation of several Tumor Response Endpoint Evaluation Committees within the franchise.   Rob’s varied and vast experience in oncology includes the following indications: breast, lung (non-small cell & small cell), head & neck, ovarian, colorectal, MDS, various leukemias, multiple myeloma and several supportive care indications.

Rob earned a Bachelor’s of Science degree in Biology at Trenton State College (now The College of New Jersey) in 1994.  Subsequently, he earned his Master’s of Business Administration in Management from Rider University in 2003, and has attended advanced training in leadership and strategy at Dartmouth University’s Tuck School of Business.

Rob OttLowRes_0164_029

We're changing our name and website to reflect our exciting new capabilities since joining Precision for Medicine. Please visit us at to see how we’re delivering the next generation of CRO services for oncology innovators.